How much is too much? Outcomes in patients using high-dose insulin glargine.

ABSTRACT:

Background and objectives

Many patients with type 2 diabetes mellitus (T2DM) do not achieve glycaemic control targets on basal insulin regimens. This analysis investigated characteristics, clinical outcomes and impact of concomitant oral antidiabetes drugs (OADs) in patients with T2DM treated with high-dose insulin glargine.

Methods

Patient-level data were pooled from 15 randomised, treat-to-target trials in patients with T2DM treated with insulin glargine ± OADs for ≥ 24 weeks. Data were stratified according to whether patients exceeded three insulin dose cut-off levels (> 0.5, > 0.7 and > 1.0 IU/kg). End-points included glycated haemoglobin A1c (A1C), fasting plasma glucose, body weight, and overall, nocturnal and severe hypoglycaemia.

Results

Data from 2837 insulin

SUBMITTER: Reid T 

PROVIDER: S-EPMC4738456 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature